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Abstract
Mycoplasma lipoproteins are recognized by Toll-like receptors (TLR), but TLRs’ role in responses to infection are unknown.
Mycoplasma pulmonis is a naturally occurring respiratory pathogen in mice. In the current study, we used TLR-transfected
HEK cells and TLR2
2/2 bone marrow-derived dendritic cells to demonstrate TLR2-mediated events are important in the
initial host-mycoplasma interactions promoting cytokine responses. As we found alveolar macrophages expressed TLR1,
TLR2 and TLR6 mRNAs, a role for TLR2 in innate immune clearance in lungs was examined. Three days post-infection,
TLR2
2/2 mice had higher M. pulmonis numbers in lungs, but not in nasal passages. However, TLR2
2/2 mice had higher lung
cytokine levels, indicating TLR2-independent mechanisms are also involved in host responses. Thus, TLR2 plays a critical role
in the ability of innate immunity to determine M. pulmonis numbers in the lung, and it is likely that early after respiratory
infection that TLR2 recognition of M. pulmonis triggers initial cytokine responses of host cells.
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Introduction
Mycoplasma infection is a leading cause of pneumonia
worldwide. In the United States, Mycoplasma pneumoniae accounts
for as many as 30% of all cases of pneumonia [1,2,3].
Mycoplasmas cause an atypical pneumonia, and in humans, M.
pneumoniae infection can exacerbate pre-existing respiratory
diseases [4,5,6]. Mycoplasma infection is also a noted problem
in livestock, with a major economic impact worldwide [7]. M.
pulmonis is a naturally occurring pathogen of rats and mice and the
etiological agent responsible for murine respiratory mycoplasmosis
(MRM) [7]. MRM causes an atypical pneumonia with both acute
and chronic stages to the disease and is an excellent animal model
used to gain insight into the pathologies caused by mycoplasma
respiratory diseases [8]. As with other mycoplasma diseases, M.
pulmonis disease has an immunopathologic element to disease
progression. In fact, elements of both the innate [9,10,11] and
adaptive [12,13,14] arms of the immune system play a role in the
progression and intrapulmonary clearance of the disease. Thus, it
is clear that the mechanisms governing the recruitment of
inflammatory cells and control of mycoplasma infection will
ultimately determine the severity of mycoplasma respiratory
disease.
The initial molecular interactions between the invading
mycoplasma and the host that play a role in the outcome of an
infection remain to be fully determined. Currently, it is believed
that attachment to the respiratory epithelium is the first step in
colonization of the host, and interactions with the alveolar
macrophages (AM) are critical in determining the levels of
infection [1]. However, the molecular intermediates that mediate
this recognition remain obscure. Toll-like receptors (TLRs) are a
highly conserved family of type I transmembrane receptors that
recognize specific pathogen-associated molecular patterns
(PAMPs), e.g. LPS, lipotechoic acid and other bacterial wall
components. The recognition of purified mycoplasma lipoproteins
to TLRs is well documented [15,16,17]. Specifically, TLR1,
TLR2 and TLR6 are implicated in the recognition of mycoplasma
lipoproteins stemming from several mycoplasma strains
[16,17,18,19]. TLR2 dimerizes with either TLR1 or TLR6 to
enhance the recognition of lipoproteins and augment the cellular
cytokine response. It is clear that TLRs play a role in the
recognition of mycoplasma lipoproteins and could have an impact
on host responses. In fact, studies suggest that M. pneumoniae may
modulate mucin production by airway cells [20,21]. One study
suggests that mycoplasma infection stimulates mucin production in
mice or a human epithelial cell line through interaction with
TLR2 [20]. The generation of Th2 type responses in a murine
asthma model is also associated with down regulation of TLR2
expression and the concomitant decreased in clearance of M.
pneumoniae [22]. These results are consistent with a role of TLR2 in
clearance of mycoplasma, which is supported by studies
demonstrating that stimulation of macrophages with TLR agonists
can initiate antimicrobial immune responses [23,24], as well as
the production of pro-inflammatory [23,25,26] and chemo-
tactic factors [27,28]. Thus, TLR signaling is likely critical in
initiating and/or influencing the host’s responses to mycoplasma
infection.
The intrapulmonary clearance of M. pulmonis, a natural
pathogen of mice, is dependent on innate immune mechanisms.
There is a body of evidence linking AMs to the intrapulmonary
clearance of the organism. AM are able to bind, ingest and kill M.
pulmonis in vitro and in vivo [9,29,30]. The intrapulmonary depletion
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strains (e.g. C57BL/6) to levels consistent with susceptible strains
(e.g. C3H) [9]. There are likely other mechanisms of innate
immunity that contribute to control of infection. Currently, the
receptors mediating the recognition of viable M. pulmonis by AM
and other cells that mediate innate immune mechanisms are
unknown. We hypothesize that AM and other innate immune cells
recognize viable M. pulmonis through TLR2-dependent mecha-
nisms, and that this recognition augments the host’s cytokine
response and their ability to resist infection. In this study, we
investigate the TLR recognition of viable M. pulmonis and
determine the effects this recognition has on disease pathogenesis.
We show that TLR1, TLR2 and TLR6 are utilized in the
recognition of viable M. pulmonis in vitro. In addition, we show the
expression of TLR1, TLR2 and TLR6 in bronchoalveolar lavage
(BAL) cells of C57BL/6J mice. Furthermore, TLR2
2/2 animals
show an impaired resistance to infection in the lower respiratory
tracts. However, TLR2
2/2 mice also had higher lung cytokine
levels, indicating TLR2-independent mechanisms are also in-
volved in later host responses. Together, our findings show that
TLR2 recognizes M. pulmonis, and this interaction can promote
early cytokine responses and resistance to mycoplasma infection in
the respiratory tract.
Results
Viable M. pulmonis recognition can be mediated by TLR2
and enhanced when TLR1 or TLR6 are co-expressed
As previous studies suggest that mycoplasma lipoproteins are
recognized by TLR2 in conjunction with TLR1 and/or TLR6
[18,19,31], these receptors may be involved in the recognition of
viable mycoplasma by macrophages and other immune cells.
Human embryonic kidney (HEK) cells are excellent for TLR-
specific mechanistic studies. In the present studies, HEK cell lines,
stably transfected to express murine TLRs, were infected with
viable M. pulmonis to determine whether these TLRs are involved
in recognizing viable M. pulmonis. TLR-mediate activation of the
HEK cells results in the production of IL-8, whose levels were used
to monitor the recognition and level of cell stimulation. As a
positive control, we stimulated the HEK cell lines with the
synthetic diacylated lipoprotein, FSL-1, a known TLR2 agonist.
As a control for cell activation independent of TLR activation, we
utilized the stock HEK cell line known to have null or low basal
expression of all the TLRs, and therefore should produce little if
any IL-8 in response to stimulation with TLR agonists. To further
confirm the specificity of our cell responses, we also stimulated the
cell lines with LPS, a known TLR4/MD2/CD14 agonist.
Stimulation of the cell lines demonstrated a role for TLR1, 2,
and 6 in the recognition of M. pulmonis. Maximum stimulation with
live M. pulmonis organisms occurred at 24 hours (Figure 1A). M.
pulmonis stimulated the TLR2-expressing cell lines to produce IL-8
(P#0.05), while the TLR4/MD2/CD14-expressing cell line was
unresponsive (Figure 1B). To confirm specificity of TLR-mediated
responses, HEK cell lines were stimulated with either a TLR4 or
TLR2 agonist. Purified TLR agonist controls, LPS and FSL-1,
had optimal and maximal stimulation at 6 hours (Figure 1B). As
expected, the TLR4/MD2/CD14-expressing cells responded to
LPS stimulation (P#0.05) while TLR2-expressing cells did not.
Similarly, with FSL-1, a TLR2 agonist, there was an increase in
IL-8 production by the TLR2-expressing cell lines with a further
enhancement of IL-8 production when either TLR1 or TLR6 was
co-expressed with TLR2 (P#0.05, Figure 1). As expected, the
TLR4/MD2/CD14-expressing cell line did not respond to FSL-1.
These results confirmed the specificity of the responses. Thus, M.
pulmonis stimulated these cells using TLR2, but not TLR4, to
stimulate a cytokine response.
Figure 1. Viable M. pulmonis recognition is mediated by TLR2 and enhanced with TLR1 or TLR6 co-expression. HEK cells or those stably
transfected to express individual TLRs and their adaptor proteins (TLR2 or TLR4/MD2/CD14) were stimulated for A) 24 hours with viable M. pulmonis
at 0.7 MOI or B) 6 hours with an E. coli derived ultra pure LPS preparation at 10 mg/ml, the TLR2/6 agonist FSL-1 at 1 mg/ml. The supernatants were
then collected and assayed for their IL-8 content. Data are expressed mean 6 SEM of IL-8 pg/ml production of each agonist. An asterisk ‘‘*’’ denotes a
P value #0.05, as compared to unstimulated cells. This experiment was done three times in triplicate.
doi:10.1371/journal.pone.0010739.g001
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responses
The above studies demonstrated that TLR2 can mediate
cellular responses to M. pulmonis infection, but there is a possibility
that other receptors, independent of TLR2, could similarly
mediate cytokine responses. To determine if TLR2 is critical in
cytokine responses from immune cells, we generated bone marrow
derived dendritic cells (BMDC) from TLR2
2/2 and wild-type
C57BL/6J mice. The BMDC were infected with viable M. pulmonis
for 24 hours. In contrast to HEK cells, murine cells do not
produce IL-8. However, IL-6 and TNF-a are produced in
response to M. pulmonis infection in vivo [32], and therefore, the
levels of these cytokines were used to measure cell activation,
rather than IL-8.
Cells from TLR2
2/2 mice were impaired in their ability to
respond to M. pulmonis infection. The BMDC from the TLR2
2/2
mice had no increase in IL-6 and TNF-a production when
compared to unstimulated controls, while BMDC from the WT
mice had significant (P#0.05) production of both cytokines in
response to M. pulmonis and the TLR2 agonist, FSL-1 (Figure 2).
Both populations of BMDC responded well to LPS, a TLR4
agonist. Thus, TLR2 was found to be critical in the optimal
cytokine production by BMDC in response to M. pulmonis
infection.
TLR1, TLR2, and TLR6 mRNA are expressed in
bronchoalveolar lavage (BAL) cells from C57BL/6J mice
Macrophages are important in the initial response to M. pulmonis
infection in lungs of mice [9,29,30]. To determine if TLR1,
TLR2, and TLR6 were expressed in pulmonary macrophages, the
BAL cells were collected from uninfected mice and TLR1, TLR2,
and TLR6 mRNA levels determined. Previous studies demon-
strated that BAL cells are predominately macrophages [9], and we
confirmed that cell collected using BAL were primarily alveolar
macrophages through their expression of CD11c and F480
[93.460.9% CD11c
+, F480
+ cells in BAL (Mean 6 SEM,
n=9)] [33].
TLR mRNA expression of BAL cells was consistent with these
receptors being expressed on these cells and having the potential to
contribute to the initial responses to mycoplasma species infection
in the lung. Specifically, TLR1, TLR2, and TLR6 mRNA were
expressed in BAL cells (Fig. 3). TLR1 was expressed at the lowest
levels of the three TLRs assayed with TLR6 having the highest
expression.
TLR2
2/2 mice are impaired in their resistance to
M. pulmonis pulmonary infection
The above studies demonstrated that TLR2 is involved in
generating cytokine responses by immune cells after mycoplasma
infection. Base on these results, it is reasonable to suggest that
TLR2 recognition is also involved in triggering innate immune
mechanisms involved in control of M. pulmonis infection. To
explore this possibility, M. pulmonis numbers were determined in
the nasal passages and the lungs in TLR2
2/2 C57BL/6J and WT
mice. C57BL/6 mice were chosen, as they are able to control the
levels of M. pulmonis pulmonary infection through innate immune
mechanisms, primarily alveolar macrophages [9]. Groups of mice
were inoculated with M. pulmonis, and 72 hours later, M. pulmonis
numbers in lungs and nasal passages were determined.
The expression TLR2 expression altered M. pulmonis numbers
recovered from infected mice. There were no clinical signs of
disease or gross inflammatory lesions in TLR2
2/2 or wild-type
C57BL/6J mice by 72 hours post-infection. However, at this time,
TLR2
2/2 mice had approximately 2-log higher numbers of M.
pulmonis in lungs, while no significant difference was found in the
nasal passages (Figure 4). We also found a corresponding increase
in IL-6 and TNF-a levels in BAL fluids from TLR2
2/2 mice
(Figure 5). Thus, TLR2
2/2 mice were impaired in their ability to
control M. pulmonis infection in the lungs, which likely leads to
increased inflammatory responses.
Discussion
The identification of receptors involved in the recognition of
viable M. pulmonis by macrophages and other cells is critical in
Figure 2. Impaired production of IL-6 and TNF-a by BMDC generated from TLR2
2/2 mice after mycoplasma stimulation. BMDC were
stimulated for 24 hours with an ultra pure LPS at 10 mg/ml or viable M. pulmonis at 50 MOI. The supernatants were then collected and assayed for
their IL-6 and TNF-a content. Data are expressed mean 6 SEM of IL-6 and TNF-a pg/ml production of each agonist. An asterisk ‘‘*’’ denotes a
P value #0.05, as compared to unstimulated cells. This experiment was done twice in triplicate.
doi:10.1371/journal.pone.0010739.g002
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responses that influence mycoplasma disease pathogenesis. TLR2-
mediated recognition of mycoplasma lipoproteins, derived from
several mycoplasma strains, is well documented in the literature
[15,16,18,19,34,35], but there are little or no studies demonstrat-
ing the ability of TLR2 to recognize infecting organisms or
determining the outcome of this interaction during infections. In
this study, we demonstrate that cellular recognition of viable M.
pulmonis is mediated by TLR2. In support, HEK cells expressing
TLR2 responded to M. pulmonis infection, and TLR2
2/2 dendritic
cells did not respond to infection whereas wild type cells produced
significant cytokine responses. Although there still might be other
TLR2-independent mechanisms involved in the recognition of M.
pulmonis, the lack of responses by TLR2
2/2 cells indicates that
TLR2 plays a critical role in the initial recognition of M. pulmonis.
In addition, the responses mediated by TLR2 on HEK cells were
significantly enhanced with the co-expression of TLR1 or TLR6.
This is consistent with previous studies demonstrating that TLR2,
in concert with TLR1 and/or TLR6, is involved in the recognition
of purified lipoproteins derived from several other mycoplasma
strains [15,16,18,19,34,35]. The current paradigm suggests that
TLR2 dimerizes with TLR1 to recognize triacylated lipoproteins
[36] and with TLR6 to recognize diacylated lipoproteins [37,38].
However, recent reports suggest that the discrimination in
recognition of bacterial lipoproteins might be more complex
[37]. In fact, a dipalmityolated lipoprotein from M. pneumoniae was
shown to activate NF-kb through TLR2, TLR6, and TLR1 [16].
To our knowledge, these are the first studies that demonstrate the
TLR recognition of infection by M. pulmonis. Thus, these studies
demonstrate M. pulmonis recognition is mediated by TLR2 and
suggests that M. pulmonis expresses both di- and triacylated
lipoproteins on its surface, which mediate these responses.
TLR2 recognition of viable mycoplasma species leads to
stimulation of innate immune mechanisms controlling the level
of infection in lungs, but these receptors have no apparent effect in
nasal passages. Similarly, other bacterial pathogens, such as Borrelia
burgdorferi [39], Streptococcus pneumoniae [40,41] and Mycobacteria
BCG [42], are recognized by TLR2, resulting in clearance of
infection in lungs. In M. pulmonis infections, the TLR2
2/2 mice
had 2-log higher M. pulmonis numbers in the lungs when compared
to their WT counterparts, but there was no difference in nasal
passages. In lungs, clearance of organisms is mediated by innate
Figure 4. TLR2
2/2 mice have higher numbers of mycoplasma in the lower respiratory tract following mycoplasma infection. Total
CFU numbers were determined in the nasal passages and the lungs in TLR2
2/2 and wild-type mice. Each mouse was inoculated with M. pulmonis.A t
72 hours post-infection, the mice were sacrificed, and the lungs and nasal washes were collected from each animal. The experiment was done twice
(total of n=9 animals). An asterisk ‘‘*’’ denotes a P value #0.05.
doi:10.1371/journal.pone.0010739.g004
Figure 3. TLR1, TLR2, and TLR6 mRNA are expressed in BAL
from mice. The BAL fluid of two mice was collected and pooled. The
cells were pelleted, RNA isolated, and cDNA was generated. The primary
transcript levels of TLR1, TLR2, and TLR6 were determined using real-
time PCR. The data is expressed as the mean 6 SEM of the relative
levels of mRNA after normalized with GAPDH mRNA expression. This
experiment was done a total of three times, and data represented were
combined from all three experiments.
doi:10.1371/journal.pone.0010739.g003
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of mice is resistant to M. pulmonis pulmonary infection due to the
effectiveness of their alveolar macrophages. We found that indeed
TLR1, TLR2, and TLR6 mRNA’s were expressed by macro-
phage-enriched BAL cells of C57BL/6J mice, supporting TLR2,
along with TLR1 and/or TLR6, as a receptor contributing to the
killing of M. pulmonis. In support, TLR activation is linked to the
enhanced phagocytosis of other microbes [43]. Interestingly,
TLR1 mRNA was expressed at the lowest levels, suggesting TLR6
may play the bigger role in TLR2-mediated responses by BAL
cells. Further studies are needed to assess whether differences in
TLR expression occur after infection and whether expression
differs between tissues, such as macrophages and epithelial cells,
which could result in differential sensitivity to infection between
cell types. Thus, TLR2 recognition of mycoplasma respiratory
infections by alveolar macrophages and other cells conferring
innate immunity leads to clearance and/or control of these
organisms in the lungs, but does not have a similar effect in nasal
passages in this same period.
Based on our in vitro studies, we predicted that cytokine pro-
duction would be reduced in infected mice; however, TLR2
2/2
mice had higher levels of cytokines in BAL fluids 72 hours after
infection, corresponding to the higher numbers of M. pulmonis in
the lung. Association of higher M. pulmonis numbers and
inflammatory cytokine levels is consistent with previous studies
[32,44]. There are clearly additional TLR2-independent mecha-
nisms in the lung, perhaps initiated by cell damage due to higher
numbers of organisms, contributing to host responses to infection.
However, TLR2 recognition of viable M. pulmonis is most likely still
important in the host’s responses early after respiratory infection.
In fact, previous studies indicate that modulation of TLR2
expression on respiratory epithelium can alter mucin production
in response to infection with the human pathogen, M. pneumoniae
[20,22]. In support, ongoing studies (unpublished) in our
laboratory demonstrate that TLR2 is involved in stimulation of
cytokine responses by respiratory epithelial by either M. pulmonis or
M. pneumoniae. Thus, both TLR2-dependent and –independent
responses are elicited after mycoplasma infection, and most likely
each contribute to the progression of infection and disease.
In summary, it is clear that TLR2-mediated events are
important in the initial interactions between the host and
mycoplasma. Using a naturally occurring murine model of
mycoplasma respiratory disease, our results demonstrate that M.
pulmonis interactions with TLR2 play as major role in host
recognition and innate immunity’s ability to control of the level of
pulmonary infection. In addition, dimers of TLR2 with TLR1 or
TLR6 are involved in the recognition on viable M. pulmonis by host
cells, in addition to macrophages, leading to stimulation of cells
and cytokine/chemokine production. As lipoproteins from other
mycoplasmas can stimulate cells using TLR2 [15,16,17], our
studies support a role of TLR2, along with TLR1 and/or TLR6,
recognition in infection and disease pathogenesis in other
mycoplasma infections, including those that affect humans. As a
supporting example, previous studies [20,22] indicate that TLR2
expression may be linked to mucin production by epithelial cells
and clearance of the human pathogen, M. pneumoniae, in a mouse
infection. Another intriguing possibility is that TLR2-mycoplasma
interactions on antigen presenting cells, such as dendritic cells and
macrophages, and other immune cells may also modulate the
types of adaptive immune responses generated in response to
infection. Studies in other systems support this possibility
[45,46,47]; in fact, IFN-c production in response to M. pneumoniae
infection of mice may in part depend upon TLR2 expression [21].
Future studies are needed to determine if TLR2, TLR1, and/or
TLR6 recognition of M. pulmonis are involved in adaptive, as well
as innate, host responses. If so, this may be harnessed in
developing new immunotherapies, including enhancing innate
resistance and optimizing vaccine strategies.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal studies were approved by University
of North Texas Health Science Center Institutional Animal Care
and Use Committee (IACUC).
Mice
C57BL/6J (wild-type, WT) and B6.129S1-TLR2
tm1Kir/J
(TLR2
2/2) mice, tested to be viral and mycoplasma free, were
obtained from The Jackson Laboratory (Bar Harbor, MN). Mice
were housed in sterile microisolator cages supplied with sterile
bedding, food and water given ad libitum. Mice used in the studies
Figure 5. TLR2
2/2 mice have higher levels of IL-6 and TNF-a in BAL fluids following mycoplasma infection. The levels of IL-6 and TNF-a
were determined from lavage fluids collected from the lungs of TLR2
2/2 and wild-type mice. Each mouse was inoculated with M. pulmonis.A t
72 hours post-infection, the mice were sacrificed, and three 1 ml BAL were collected from each animal, and cytokine levels in the BAL fluids were
determined. The experiment was done twice (total of n=8 animals). An asterisk ‘‘*’’ denotes a P value #0.05.
doi:10.1371/journal.pone.0010739.g005
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studies. Before experimental infection, mice were anesthetized
with an intramuscular injection of ketamine/xylazine.
Cell lines
Human embryonic kidney 293 (HEK) cell lines were obtained
from InvivoGen, (San Diego, CA), and included HEK (control)
and HEK cells stably transfected to express murine TLR1, TLR2,
TLR6, TLR2/6, TLR2/1 or TLR4/MD2/CD14. All cells were
cultured in DMEM high glucose containing 10% FBS and 2 mM
L-glutamine without the use of antibiotics, and the HEK cell lines
were used prior to 10 passages.
Mycoplasma
The UAB CT strain of M. pulmonis was used in all experiments.
Stock cultures were grown, as previously described [48], for in vitro
stimulation studies 1 ml aliquots frozen at 280uC were thawed
and grown in 9 ml Hayflick’s medium for 3 hours at 200 rpm.
The resulting growth was spun down at 10,000 rpm for
20 minutes, washed in serum free Dulbecco’s Modified Eagle
Medium (DMEM) high glucose (Hyclone, Logan, UT) and
reconstituted in a total volume of 5-ml of serum free DMEM.
For infections, mice were anesthetized with an intraperitoneal
injection of ketamine/xyalzine, and then they received an
intranasal inoculum of 20 ml containing 2610
6 cfu of M. pulmonis
strain CT [48].
Generation of bone marrow derived dendritic cells
(BMDC)
Bone marrow derived dendritic cells were generated as
previously described [49]. Femora and tibia were collected from
mice, and the bones were suspended in wash medium containing
RPMI 1640 (Hyclone), 10% FBS (Hyclone), antibiotic/antimy-
cotic solution (Life Technologies, Grand Island, NY), and HEPES
buffer (Fisher Scientific, Pittsburgh, PA). The bones were twice
washed in medium and also soaked in 70% ethanol between
washes. The epiphyses were cut, and the marrow flushed from the
bones with wash medium. Epiphyses were finely minced and
added with the flushed marrow. The suspension was passed
through a 250 mm nylon mesh to remove any unwanted debris.
The cell suspension was then spun down, and red cells removed
using ACK lysis buffer [50]. The cells were then spun down, re-
suspended in wash medium and counted. Once counted, the cells
were placed in cell culture flasks at a concentration of 10
7 cells/ml.
The cells were cultured in the presence of IL-4 (20 ng/ml,
Invitrogen) and GM-CSF (20 ng/ml, Invitrogen). Culture medium
was changed every two days, and the cells were harvested on
day 6.
In vitro cell stimulations
The HEK stable transfectants (InvivoGen) were seeded at
2610
5 cells/well in 24-well tissue culture treated plates. The cells
were washed and seeded in serum-free DMEM high glucose cell
culture medium (Hyclone). The agonists, FSL-1 (1mg/ml, Invivo-
Gen), Ultrapure LPS, E. coli 0111:B4 (10 mg/ml, InvivoGen), and
whole organism, M. pulmonis [multiplicity of infection (MOI) of 0.7
cfu/cell], were suspended in serum-free DMEM high glucose
(Hyclone) and added to the wells for a total volume of 500 ml/well.
The supernatants were collected at 6- and 24-hour time points.
BMDC were similarly stimulated with Ultrapure LPS or M.
pulmonis (MOI of 50), and cell culture supernatants were collected
at 24 hours after stimulation. Culture supernatants were stored at
280uC until assayed.
Bronchoalveolar lavage (BAL) cells and fluid
The BAL was performed as previously described [51]. Mice
were killed by lethal injection, and their tracheas were exposed
and ligated distal to the larynx. A sterile 22G ProtectIV Plus
catheter (MEDEX, Carlsbad, CA) was inserted approximately 2 to
3 mm into the lumen, and the lungs were then lavaged 3 times
with 1 ml aliquots of PBS solution (Hyclone). The lavages were
pooled, and cells pelleted using centrifugation at 2006g for 10 min
at 4uC. The BAL fluids were aliquoted and stored at 280uC, and
cell pellets were resuspended in 500 ml of Trizol (Invitrogen Life
Technologies, Carlsbad CA).
Alveolar macrophages express CD11c in addition to other
macrophage markers, such as F480 [33]. BAL cells were
suspended in 50 ml of staining buffer (16 PBS, 2mM EDTA,
2% FBS) with diluted antibodies PE anti-mouse CD11c (BD
Pharmingen, catalog # 553802), APC anti-mouse F4/80 (Caltag
Laboratories, catalog # MF48005) and purified anti-mouse
CD16/CD32 Fc Block (BD Pharmingen, catalog # 553142).
Cells were incubated with antibodies for 30 min at 4uC, and then
quenched with 1 mL of staining buffer and centrifuged (just as
above). Nine samples were stained and 2 samples were unstained
(except for the FcBlock). Samples were resuspended in 300 mlo f
staining buffer and run on a BD LSRII Flow Cytometer using BD
FACSDiva Software v6. The samples were analyzed using FlowJo
v9.0.1 (TreeStar). Stained samples were compared to unstained
samples and alveolar macrophages were identified as CD11c
+ (PE)
and F4/80
+(APC).
RNA extraction
RNA from BAL cells was isolated using Trizol RNA isolation
reagent, as recommended by the manufacturer (Invitrogen) [44].
500 ml of TRIZOL were added to the pellet and pipetted to ensure
lysis of the sample. The homogenates were frozen at 280uC until
needed. Chloroform was added to the thawed homogenates and
centrifuged at 12,0006g (4uC) for 30 min. RNA was precipitated
by adding isopropanol to the aqueous phase and centrifuging
samples at 12,0006g (4uC) for 10 min. The RNA pellet from each
sample was washed twice with 75% ethanol by vortexing and
subsequent centrifugation for 5 min at 7,5006g, and then re-
suspended in diethylpyrocarbonate-treated water. The samples
were stored at 280uC until further use.
Cytokine ELISA
Human IL-8 was measured using OptEIA IL-8 ELISA set (BD
Pharmingen). BAL fluid and supernatant from BMDC stimulation
experiments were evaluated for the cytokine expression of IL-6
and TNF-a using a mouse cytokine Milliplex
TM Map kit
(Millipore, Billerica, MA). Cytokine assays were run as manufac-
turer instructed. Samples were read using a Bio-Plex 100 system
(Bio-Rad, Hercules, CA). Cytokine levels were determined by
comparison with standard curves generated from murine recom-
binant cytokines and analyzed using Bio-Plex Manager 4.0
software (Bio-Rad).
Toll-Like receptor mRNA detection by real time-PCR
cDNA was synthesized from total RNA samples in a 100-ml
reaction using the Taqman Gold RT-PCR kit (Applied Biosys-
tems, Foster City, CA) according to the manufacturer’s instruc-
tions. Sybr-green real-time PCR was performed using RT
2 SYBR
Green/ROX qPCR Master Mix and primers for TLR1, TLR2,
TLR6 and the housekeeping gene GAPDH (SuperArray Biosci-
ence Corporation, Frederick, MD). Real-time PCR was performed
in 25 ml SmartCycler tubes (Cepheid, Sunnyvale, CA), and the
TLR2 and Mycoplasma Infection
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system (Cepheid) at 95.0uC for 10 min, followed by 40 cycles of
95.0uC for 15 s and 60.0uC for 60 s. The threshold of the growth
curve (CT) was set at a value of 30 using the SmartCycler software.
The expression of the housekeeping gene, GAPDH, was used to
normalize the data. The formula for the normalization (DCT)
between the amplified TLR gene and the normalizer (GAPDH) is
DCT~CT(GAPDH){CT(cytokine)
Determination of mycoplasma numbers
Following infection, lungs and nasal passages were quantita-
tively cultured as described elsewhere [48]. Lungs were minced,
and both lungs and nasal passage washes were placed in
mycoplasma broth medium. The samples were sonicated for 45–
60 seconds, and 1:10 serial dilutions were prepared. 20 ml of each
dilution were plated onto mycoplasma agar medium. After 7 days
of incubation at 37uC, cfu were counted.
Statistical Analyses
Data results were analyzed using two-way ANOVA followed by
multigroup comparisons or Students’ t-test when appropriate.
When necessary, the data was logarithmically transformed prior to
analysis. The data were analyzed using the Instat and Prism
software programs (GraphPad, San Diego, CA). A P value #0.05
was considered statistically significant.
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